Oramed Pharmaceuticals (ORMP) stock price, revenue, and financials

Oramed Pharmaceuticals market cap is $52.3 m, and annual revenue was $2.70 m in FY 2019

$52.3 M

ORMP Mkt cap, 27-Mar-2020

$674 K

Oramed Pharmaceuticals Revenue Q1, 2020
Oramed Pharmaceuticals Cash, 30-Nov-20193.2 M
Oramed Pharmaceuticals EV49.2 M

Oramed Pharmaceuticals Income Statement

Annual

USDFY, 2012FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

641.0k2.5m2.4m2.7m

Cost of goods sold

490.0k187.0k90.0k

Gross profit

151.0k2.3m2.6m

Gross profit Margin, %

24%92%97%

Sales and marketing expense

284.9k

R&D expense

1.7m3.3m7.7m10.3m12.0m13.5m

General and administrative expense

1.2m2.6m2.5m2.8m4.1m3.7m

Operating expense total

3.2m5.9m10.2m13.0m16.1m17.2m

Depreciation and amortization

4.0k4.0k

EBIT

(2.9m)(5.9m)7.4m

Interest expense

138.0k

Interest income

13.1k225.0k168.0k792.0k903.0k1.1m

Pre tax profit

(3.3m)(5.7m)7.2m(9.6m)(10.1m)(12.7m)(14.1m)

Income tax expense

90.2k4.0k1.0k1.3m400.0k300.0k

Net Income

(3.3m)(5.7m)7.2m

Oramed Pharmaceuticals Balance Sheet

Quarterly

USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

1.5m1.8m1.3m5.5m2.0m1.1m1.4m3.3m2.5m6.7m1.1m1.9m3.2m3.3m2.3m1.5m1.7m1.3m3.3m3.7m3.9m3.2m

Accounts Receivable

86.0k46.7k135.4k76.0k439.8k333.7k73.1k267.1k27.0k2.0k

Prepaid Expenses

18.5k12.8k21.0k18.8k36.4k62.3k172.9k245.6k97.5k120.0k129.0k112.0k417.0k421.0k430.0k151.0k127.0k163.0k224.0k209.0k727.0k609.0k

Current Assets

3.9m3.1m2.5m6.8m5.9m4.8m8.0m23.7m16.0m24.5m18.3m15.2m26.0m25.1m30.5m29.8m26.3m19.1m21.1m23.6m29.7m30.7m

PP&E

11.3k7.8k2.1k2.5k1.9k5.7k8.8k12.2k13.5k15.0k13.0k12.0k11.0k17.0k15.0k16.0k17.0k17.0k18.0k17.0k23.0k27.0k

Total Assets

3.9m3.1m2.5m6.8m6.0m4.8m8.0m23.7m22.5m24.6m23.0m23.9m38.4m36.3m44.9m41.8m39.8m41.5m38.3m34.7m43.6m31.1m

Accounts Payable

357.3k534.9k308.6k287.3k422.1k398.8k621.3k302.6k447.8k795.0k570.0k768.0k829.0k646.0k2.2m2.4m2.5m2.6m2.2m3.1m3.0m1.8m

Short-term debt

46.0k

Current Liabilities

424.4k582.2k355.9k334.6k469.4k446.0k668.5k349.8k495.0k827.0k605.0k1.3m1.5m1.3m4.7m4.9m5.0m5.1m4.7m5.6m4.2m4.6m

Long-term debt

60.0k

Non-Current Liabilities

160.8k162.0k146.8k240.4k239.9k241.1k31.9k32.4k31.9k36.0k36.0k38.0k4.1m4.0m16.2m15.6m14.9m13.7m13.1m12.4m10.6m9.3m

Total Debt

106.0k

Total Liabilities

744.1k502.7k

Common Stock

70.1k70.2k70.4k86.5k86.7k86.7k95.4k117.3k119.5k129.0k129.0k138.0k157.0k157.0k158.0k159.0k159.0k170.0k171.0k172.0k207.0k209.0k

Additional Paid-in Capital

18.3m18.3m18.4m24.8m25.0m25.3m30.1m46.7m47.6m53.2m53.5m59.7m71.6m71.8m72.4m72.8m73.0m80.9m81.9m82.6m99.7m100.6m

Retained Earnings

(15.0m)(16.0m)(16.6m)(18.9m)(20.1m)(21.3m)(23.2m)(24.4m)(26.2m)(29.7m)(31.4m)(37.4m)(39.3m)(41.3m)(48.7m)(51.8m)(53.8m)(59.0m)(61.9m)(66.3m)(71.0m)(83.6m)

Total Equity

3.3m2.4m2.0m6.2m5.2m4.2m7.3m23.3m22.0m23.7m22.3m22.5m32.7m31.0m24.0m21.3m19.8m22.7m20.5m16.7m28.9m207.0k207.0k17.2m

Financial Leverage

1.2 x1.3 x1.3 x1.1 x1.1 x1.2 x1.1 x1 x1 x1 x1 x1.1 x1.2 x1.2 x1.9 x2 x2 x1.8 x1.9 x2.1 x1.5 x1.8 x

Oramed Pharmaceuticals Cash Flow

Annual

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(3.3m)(4.2m)(5.7m)(11.0m)(10.5m)(12.7m)(14.4m)

Depreciation and Amortization

14.7k5.4k6.0k4.0k4.0k5.0k6.0k8.0k

Accounts Payable

203.1k(146.2k)475.0k

Cash From Operating Activities

(2.3m)(3.4m)(4.1m)(4.9m)4.7m(5.8m)(14.7m)(12.9m)

Purchases of PP&E

(2.1k)(6.4k)(14.0k)(1.0k)(9.0k)(7.0k)(5.0k)(15.0k)

Cash From Investing Activities

1.8m(4.6m)(13.1m)(3.3m)(16.0m)4.3m(7.0m)11.3m

Cash From Financing Activities

3.5m5.8m16.6m9.7m12.0m1.6m22.7m

Net Change in Cash

2.9m(2.2m)(510.0k)1.5m694.0k62.0k1.0m(1.7m)

Income Taxes Paid

300.0k

Oramed Pharmaceuticals Ratios

USDY, 2019

EV/CFO

-16.4 x

Financial Leverage

1.8 x